Article
10 Jul 2026
Special Master Declines Categorical Exemption Of MMRs And Brand Sponsors From Associated Entity Designation Under House Settlement
CONTRIBUTING SINCE MARCH 2011
Buchanan Ingersoll & Rooney PC
With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
POPULAR TOPICS
Food, Drugs, Healthcare, Life Sciences
International Law
Employment and HR
Cannabis & Hemp
Technology
Buchanan Ingersoll & Rooney PC are most popular:
- within Finance and Banking, Government, Public Sector and Environment topic(s)
- with readers working within the Environment & Waste Management and Technology industries
DETAILS
United States
+1 412 562 8800
Union Trust Building
501 Grant Street
Suite 200
Pittsburgh
United States
Contact Firm
COMPANY CONTENT
Article
10 Jul 2026
FDA Inspection Implications For MedSpas And Wellness Centers
Article
10 Jul 2026
The Rise Of ERISA Forfeiture Litigation And What Plan Sponsors Must Know
Article
09 Jul 2026
Claim Indefiniteness Under 35 USC 112
Article
09 Jul 2026
Illinois SB 315: Pioneering AI Safety Regulations And The Future Of Responsible AI Governance
Article
08 Jul 2026
Eligibility Issues Explained: Constellation Designs, LLC
Article
06 Jul 2026
Navigating Global Business Challenges: The Strategic Impact Of CFIUS And Tariffs In The Modern Economy
Article
02 Jul 2026
DOJ’s 2026 Health Care Fraud Takedown: Why Pharmacies Should Act Before An Audit Becomes An Investigation
Article
02 Jul 2026
Texas Telehealth Pharmacy Rule Signals A New Compliance Era: What Every Pharmacy Should Know About The Board’s Proposed Informed Consent Requirements
Article
02 Jul 2026
PBM Terminations: Small Audit Discrepancies Can Still Put Your Pharmacy At Risk
Article
02 Jul 2026
First Declination Of Prosecution Under DOJ Corporate Enforcement And Voluntary Self-Disclosure Policy
Article
01 Jul 2026
Rhode Island Joins The PBM Oversight Movement: What Senate Bill 3060 Means For Pharmacies, Health Plans And PBM Regulation
Article
01 Jul 2026
Arizona Joins The Growing Movement To Separate PBMs From Pharmacy Ownership
Article
30 Jun 2026
The Clock Is Ticking: What The Faster Labor Contracts Act Means For Employers
Article
30 Jun 2026
Cassidy’s 340B Reform Discussion Draft Signals A Shift In The Future Of The 340B Program
Article
29 Jun 2026
West Virginia Board Of Pharmacy Adopts New Inspection Rule: What Pharmacies Need To Know Before July 1, 2026
Article
29 Jun 2026
Florida Takes Aim At CVS Caremark: Why The Sunshine State’s Investigation Could Be A Turning Point For PBM Oversight
Article
26 Jun 2026
Maryland Expands Prescriber–Pharmacist Agreements And Opens New Opportunities For Opioid Use Disorder Treatment
Article
26 Jun 2026
Tennessee’s FAIR Rx Act Litigation: Why Independent Pharmacies Should Watch This PBM Fight Closely
Article
25 Jun 2026
U.S. Sanctions On Iran: Settlement Negotiations, General License X And Status Update
AWARDS
